References
- ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
- ScheenAJEvaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerationsExpert Opin Drug Metab Toxicol201410564766324387329
- InzucchiSEZinmanBWannerCSGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trialsDiab Vasc Dis Res20151229010025589482
- GremplerRThomasLEckhardtMEmpagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitorsDiabetes Obes Metab2012141839021985634
- EMAJardiance EPAR: Public Assessment Report2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdfAccessed March 17, 2016
- EMAFicha técnica Forxiga2016 Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdfAccessed March 17, 2016
- EMAFicha técnica Invokana2016 Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdfAccessed March 17, 2016
- NealBPerkovicVde ZeeuwDRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trialAm Heart J20131662217223e21123895803
- NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med2007356242457247117517853
- DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet200536694931279128916214598
- SciricaBMBhattDLBraunwaldESaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusN Engl J Med2013369141317132623992601
- GreenJBBethelMAArmstrongPWEffect of sitagliptin on cardiovascular outcomes in type 2 diabetesN Engl J Med2015373323224226052984
- WhiteWBCannonCPHellerSRAlogliptin after acute coronary syndrome in patients with type 2 diabetesN Engl J Med2013369141327133523992602
- AstraZenecaBristol-Myers SquibbThe TIMI Study GroupHadassah Medical OrganizationMulticenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58)ClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited 2016 Mar 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534?term=declare+timi+58&rank=1. NLM identifier: NCT01730534Accessed November 7, 2016
- Janssen Research & DevelopmentThe George Institute for Global Health (Australia)CANVAS – CANagliflozin cardioVascular Assessment Study (CANVAS)ClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited 2016 Mar 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01032629?term=canvas&rank=1. NLM identifier: NCT01032629Accessed November 7, 2016
- Janssen Research & DevelopmentThe George Institute for Global Health (Australia)A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R)ClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited 2016 17 Mar]. Available from: https://clinicaltrials.gov/ct2/show/NCT01989754?term=canvas&rank=5. NLM identifier: NCT01989754Accessed November 7, 2016